Sodium Citrate

Summary

Sodium Citrate (CHEMBL1355) is an approved small-molecule anticoagulant (ATC B05CB02); indicated across 11 conditions including anemia and depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B05CB02
• Indications: 11 conditions
• Clinical trials: 17
• Chemistry: 258.07 Da · C6H5Na3O7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1355
Name	Sodium Citrate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6224
ChEBI	CHEBI:53258
ATC	B05CB02
Molecular formula	C6H5Na3O7
Molecular weight	258.07
InChIKey	HRXKRNGNAMMEHJ-UHFFFAOYSA-K

SMILES: C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Na+].[Na+].[Na+]

IUPAC name: trisodium;2-hydroxypropane-1,2,3-tricarboxylate

ChEBI definition: The trisodium salt of citric acid.

Pharmacological roles (ChEBI): anticoagulant.

Other ChEBI roles (chemical / environmental): flavouring agent.

Also known as: Anhydrous sodium citrate, Anhydrous trisodium citrate, Anticoagulant sodium citrate, Canesten oasis, Citric acid, trisodium salt, Citrosodine, Cymalon, Cystemme, Cystocalm, Cystoleve, E-331(III)

Patent coverage: 206,185 distinct patent families (550,390 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Carbonic anhydrase 4, Carbonic anhydrase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CA4	7	Ki	99	nM	CHEMBL_ACT_1432100

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
anemia	4	MONDO:0002280	EFO:0004272
depressive disorder	4	MONDO:0002050	MONDO:0002009

8 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
dry eye syndrome	3	MONDO:0006733	EFO:1000906
graft versus host disease	3	MONDO:0013730	EFO:0004599
anterior uveitis	3	MONDO:0006651	EFO:1000811
autosomal dominant polycystic kidney disease	2	MONDO:0004691	EFO:1001496
cataract	2	MONDO:0005129	MONDO:0005129
type 1 diabetes mellitus	1	MONDO:0005147	MONDO:0005147
osteoarthritis	1	MONDO:0005178	MONDO:0005178
propionic acidemia	1	MONDO:0011628	MONDO:0011628

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE4	5
Not specified	5
PHASE3	2
PHASE2	2
PHASE1	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00286273	PHASE4	COMPLETED	Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration
NCT00483795	PHASE4	COMPLETED	Pilot Evaluation of Two Multipurpose Solutions in Regards to Corneal Staining
NCT00586131	PHASE4	COMPLETED	Arterial pH and Total Body Nitrogen Balances in APD
NCT04756427	PHASE4	TERMINATED	Sodium Citrate 4% Locking Solution for Children Requiring Home Parenteral Nutrition
NCT05191290	PHASE4	COMPLETED	Comparison of Biocompatibility of Plasmapheresis Procedures With Citrate and Heparin Anticoagulation
NCT01350882	PHASE3	COMPLETED	Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
NCT01835912	PHASE3	COMPLETED	Chronic Versus Acute Dosing of Sodium Citrate for Swimming 200m
NCT06204432	PHASE2	ACTIVE_NOT_RECRUITING	Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction
NCT04284657	PHASE2	COMPLETED	Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
NCT01421160	PHASE1	WITHDRAWN	Regulating Urine pH Levels to Alleviate Chronic Joint Pain
NCT05067270	PHASE1	COMPLETED	A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus
NCT00968565	EARLY_PHASE1	COMPLETED	Study Using Citrate to Replace Heparin in Babies Requiring Extracorporeal Membrane Oxygenation (ECMO)
NCT06994312	Not specified	NOT_YET_RECRUITING	The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration
NCT00004361	Not specified	COMPLETED	Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects
NCT01591226	Not specified	COMPLETED	Caffeine and Sodium Citrate Ingestion
NCT01689753	Not specified	COMPLETED	Effect of the TEGO Connector in Preventing Tunneled Cuffed Hemodialysis Catheters From Dysfunction and/or Bacteremia
NCT02714075	Not specified	COMPLETED	Comparison of Iron Absorption From Extruded FePP-fortified Rice Containing Zinc, Citric Acid/Trisodium Citrate and EDTA

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).